Calithera to Present at the Jefferies and JMP Securities Healthcare Conferences in June
SOUTH SAN FRANCISCO, Calif., June 06, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, announced today Susan M. Molineaux, Ph.D, founder, CEO and President and Keith Orford, M.D., Ph.D., Senior Vice President of Clinical Development will participate in the following two investment conferences in June:
The Jefferies 2018 Healthcare Conference at the Grand Hyatt in New York City. Calithera will present at the conference today, June 6, 2018 at 8:00 a.m. Eastern time. A live webcast of this presentation will be accessible via the media and investors page of www.calithera.com. An archived replay of the webcast will be available on the Company’s website for 30 days following the conference.
The JMP Securities 2018 Life Sciences Conference at the St.Regis in New York City. Calithera will participate in a panel discussion on June 20, 2018 at 3:30 p.m. Eastern time.
Calithera is a clinical-stage biopharmaceutical company focused on fighting cancer by discovering, developing, and commercializing novel small molecule drugs that target tumor and immune cell metabolism. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “poised” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera’s stock price. Additional information concerning these and other risk factors affecting Calithera’s business can be found in Calithera’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, and other periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
SOURCE: Calithera Biosciences, Incorporated